VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Atevirdine mesylate
Preclinical
Small molecule
N
National Institute of Allergy and Infectious Diseases (NIAID)
1
Indications
4
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Drug Resistance
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Drug Resistance
Preclinical
Completed
Clinical
Trials by Indication
[1]
Concentration
2 trials
A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 1
·
NCT00000742
·
15 enrolled
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 1
·
NCT00000753
·
30 enrolled
Drug Resistance
1 trial
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
Completed
·
P
Pharmacia and Upjohn
·
N/A
·
NCT00002094
HIV
1 trial
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
Completed
·
P
Pharmacia and Upjohn
·
Phase 2
·
NCT00002322
Sources
References
[1]
ClinicalTrials.gov
—
4 trial records for Atevirdine mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Atevirdine mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Atevirdine mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
N
National Institute of Allergy and Infectious Diseases (NIAID)
Related News